Vincerx Pharma Inc :
* VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES
* VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025
* VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943
* VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY
* VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.
Source text for Eikon: Further company coverage:
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。